The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale

Iain Bressendorff, Ditte Hansen, Morten Schou, Charlotte Kragelund, Lisbet Brandi, Iain Bressendorff, Ditte Hansen, Morten Schou, Charlotte Kragelund, Lisbet Brandi

Abstract

Introduction: Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular disease and mortality, which is thought to be caused by increased propensity towards vascular calcification (VC). Magnesium (Mg) inhibits phosphate-induced VC in vitro and in animal models and serum Mg is inversely associated with cardiovascular mortality in predialysis CKD and in end-stage renal disease. This paper will describe the design and rationale of a randomised double-blinded placebo-controlled multicentre clinical trial, which will investigate whether oral Mg supplementation can prevent the progression of coronary artery calcification (CAC) in subjects with predialysis CKD.

Methods and analysis: We will randomise 250 subjects with estimated glomerular filtration rate of 15 to 45 mL/min/1.73 m2 to 12 months treatment with either slow-release Mg hydroxide 30 mmol/day or matching placebo in a 1:1 ratio. The primary end point is change in CAC score as measured by CT at baseline and after 12 months treatment. Secondary end points include change in pulse wave velocity, bone mineral density, measures of mineral metabolism and clinical end points related to cardiovascular and renal events.

Ethics and dissemination: This trial has been approved by the local biomedical research ethics committees and data protection agencies and will be performed in accordance with the latest revision of the Helsinki Declaration. The trial will examine for the first time the effect of increasing the uptake of a putative VC inhibitor (ie, Mg) on progression of CAC in subjects with predialysis CKD.

Trial registration number: NCT02542319, pre-results.

Keywords: Magnesium; chronic kidney disease; mineral metabolism; randomised clinical trial; vascular calcification.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Inclusion and exclusion criteria.
Figure 2
Figure 2
Trial design of effect of oral magnesium on vascular calcification in chronic kidney disease. BID, twice daily.
Figure 3
Figure 3
Schedule for enrolment, interventions and assessments.

References

    1. Coresh J, Selvin E, Stevens LA, et al. . Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038–47. 10.1001/jama.298.17.2038
    1. Go AS, Chertow GM, Fan D, et al. . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–305. 10.1056/NEJMoa041031
    1. Budoff MJ, Rader DJ, Reilly MP, et al. . Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic renal insufficiency cohort) Study. Am J Kidney Dis 2011;58:519–26. 10.1053/j.ajkd.2011.04.024
    1. Chirinos JA, Khan A, Bansal N, et al. . Arterial stiffness, central pressures, and incident hospitalized heart failure in the chronic renal insufficiency cohort study. Circ Heart Fail 2014;7:709–16. 10.1161/CIRCHEARTFAILURE.113.001041
    1. Bansal N, McCulloch CE, Lin F, et al. . Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. Kidney Int 2016;90:1348–56. 10.1016/j.kint.2016.08.009
    1. Matsushita K, Sang Y, Ballew SH, et al. . Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol 2015;26:439–47. 10.1681/ASN.2014020173
    1. Yamada S, Giachelli CM. Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho. Bone 2016. Epub ahead of print: pii: S8756-3282(16)30345-3 10.1016/j.bone.2016.11.012
    1. Montezano AC, Zimmerman D, Yusuf H, et al. . Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 2010;56:453–62. 10.1161/HYPERTENSIONAHA.110.152058
    1. Kircelli F, Peter ME, Sevinc Ok E, et al. . Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 2012;27:514–21. 10.1093/ndt/gfr321
    1. Louvet L, Büchel J, Steppan S, et al. . Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 2013;28:869–78. 10.1093/ndt/gfs520
    1. Montes de Oca A, Guerrero F, Martinez-Moreno JM, et al. . Magnesium inhibits wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One 2014;9:e89525 10.1371/journal.pone.0089525
    1. Xu J, Bai Y, Jin J, et al. . Magnesium modulates the expression levels of calcification-associated factors to inhibit calcification in a time-dependent manner. Exp Ther Med 2015;9:1028–34. 10.3892/etm.2015.2215
    1. Zelt JG, McCabe KM, Svajger B, et al. . Magnesium modifies the impact of calcitriol treatment on vascular calcification in experimental chronic kidney disease. J Pharmacol Exp Ther 2015;355:451–62. 10.1124/jpet.115.228106
    1. Sonou T, Ohya M, Yashiro M, et al. . Magnesium prevents phosphate-induced vascular calcification via TRPM7 and Pit-1 in an aortic tissue culture model. Hypertens Res 2017. Epub ahead of print: 26 Jan 2017 10.1038/hr.2016.188
    1. Alesutan I, Tuffaha R, Auer T, et al. . Inhibition of osteo/chondrogenic transformation of vascular smooth muscle cells by MgCl2 via calcium-sensing receptor. J Hypertens 2017;35:523–32. 10.1097/HJH.0000000000001202
    1. Kanbay M, Yilmaz MI, Apetrii M, et al. . Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 2012;36:228–37. 10.1159/000341868
    1. Sakaguchi Y, Fujii N, Shoji T, et al. . Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014;85:174–81. 10.1038/ki.2013.327
    1. Sakaguchi Y, Fujii N, Shoji T, et al. . Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One 2014;9:e116273 10.1371/journal.pone.0116273
    1. Ishimura E, Okuno S, Yamakawa T, et al. . Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007;20:237–44.
    1. João Matias P, Azevedo A, Laranjinha I, et al. . Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif 2014;38(3-4):244–52. 10.1159/000366124
    1. Fein P, Weiss S, Ramos F, et al. . Serum magnesium concentration is a significant predictor of mortality in peritoneal Dialysis patients. Adv Perit Dial 2014;30:90–3.
    1. de Roij van Zuijdewijn CL, Grooteman MP, Bots ML, et al. . Serum magnesium and sudden death in European Hemodialysis Patients. PLoS One 2015;10:e0143104 10.1371/journal.pone.0143104
    1. Lacson E, Wang W, Ma L, et al. . Serum magnesium and mortality in Hemodialysis Patients in the United States: a Cohort Study. Am J Kidney Dis 2015;66:1056–66. 10.1053/j.ajkd.2015.06.014
    1. Kurita N, Akizawa T, Fukagawa M, et al. . Contribution of dysregulated serum magnesium to mortality in hemodialysis patients with secondary hyperparathyroidism: a 3-year cohort study. Clin Kidney J 2015;8:744–52. 10.1093/ckj/sfv097
    1. Tin A, Grams ME, Maruthur NM, et al. . Results from the Atherosclerosis risk in communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int 2015;87:820–7. 10.1038/ki.2014.331
    1. Van Laecke S, Nagler EV, Verbeke F, et al. . Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 2013;126:825–31. 10.1016/j.amjmed.2013.02.036
    1. Sakaguchi Y, Iwatani H, Hamano T, et al. . Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease. Kidney Int 2015;88:833–42. 10.1038/ki.2015.165
    1. Sakaguchi Y, Hamano T, Nakano C, et al. . Association between Density of coronary artery calcification and serum magnesium levels among patients with chronic kidney disease. PLoS One 2016;11:e0163673 10.1371/journal.pone.0163673
    1. Turgut F, Kanbay M, Metin MR, et al. . Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008;40:1075–82. 10.1007/s11255-008-9410-3
    1. Mortazavi M, Moeinzadeh F, Saadatnia M, et al. . Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 2013;69:309–16. 10.1159/000346427
    1. Agatston AS, Janowitz WR, Hildner FJ, et al. . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32. 10.1016/0735-1097(90)90282-T
    1. Pasch A, Farese S, Gräber S, et al. . Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012;23:1744–52. 10.1681/ASN.2012030240
    1. Russo D, Corrao S, Miranda I, et al. . Progression of coronary artery calcification in predialysis patients. Am J Nephrol 2007;27:152–8. 10.1159/000100044
    1. Russo D, Miranda I, Ruocco C, et al. . The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72:1255–61. 10.1038/sj.ki.5002518
    1. Bressendorff I, Hansen D, Schou M, et al. . Oral magnesium supplementation in chronic kidney disease stages 3 and 4: efficacy, Safety, and effect on serum calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial. Kidney Int Rep 2017;2:380–9. 10.1016/j.ekir.2016.12.008
    1. Smith ER, Ford ML, Tomlinson LA, et al. . Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol 2014;25:339–48. 10.1681/ASN.2013060635
    1. Bøhmer T, Røseth A, Holm H, et al. . Bioavailability of oral magnesium supplementation in female students evaluated from elimination of magnesium in 24-hour urine. Magnes Trace Elem 1990;9:272–8.
    1. Walker AF, Marakis G, Christie S, et al. . Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnes Res 2003;16:183–91.
    1. de Francisco AL, Leidig M, Covic AC, et al. . Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707–17. 10.1093/ndt/gfq292
    1. Block GA, Wheeler DC, Persky MS, et al. . Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407–15. 10.1681/ASN.2012030223
    1. Seifert ME, de las Fuentes L, Rothstein M, et al. . Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol 2013;38:158–67. 10.1159/000353569

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi